• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   Open Access Home
  • Rektörlüğe Bağlı Bölümler
  • Araştırma Çıktıları
  • Öksüz Yayınlar Koleksiyonu - WoS
  • View Item
  •   Open Access Home
  • Rektörlüğe Bağlı Bölümler
  • Araştırma Çıktıları
  • Öksüz Yayınlar Koleksiyonu - WoS
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less

Date

2017

Author

Ozaslan, Ersin
Karaca, Halit
Koca, Sinan
Sevinc, Alper
Hacioglu, Bekir
Ozkan, Metin
Ozcelik, Melike
Duran, Ayse O.
Hacibekiroglu, Ilhan
Yildiz, Yasar
Tanriverdi, Ozgur
Menekse, Serkan
Aksoy, Asude
Bozkurt, Oktay
Urvay, Semiha
Uysal, Mukremin
Demir, Hacer
Ciltas, Aydin
Dane, Faysal

Metadata

Show full item record

Abstract

The objectives of this study were to compare progression-free survival (PFS) with somatostatin analog (SSA) versus chemotherapy (CTx) in first-line therapy and to determine the patient group in which these treatments were more effective in neuroendocrine tumors (NETs) with a Ki-67 index of 20% or less. Patients who received SSA or CTx and had unresectable locally advanced and metastatic NETs with a Ki-67 index of 20% or less were retrospectively selected from 13 centers in the Turkish database between 2000 and 2015. One hundred and sixty-five patients were enrolled. The median age was 56 years and the male-to-female ratio was 1.09. Seventy-four (45%) patients were of grade 1 NET and 91 (55%) were of grade 2. SSA was given to 104 patients, whereas 61 were treated with CTx. The objective response rate after SSA was 15.4%; another 73.1% had stable disease. The objective response rate after CTx was 36.1%, and 40.9% had stable disease (P = 0.008). The median PFS in SSA patients was 21 months (95% confidence interval: 12.4-29.6), and 8 months for CTx (95% confidence interval: 5.5-10.6) (P < 0.001). There was no significant difference between PFS of receiving SSA and CTx in pancreatic neuroendocrine tumor (PNET) patients; however, the PFS of receiving SSA was longer in non-PNET patients (P < 0.001). SSA was better treatment in advanced NET patients with a Ki-67 index of less than 5%, having a primary resected and a performance status of 0 (P < 0.05). SSA may be preferred over CTx in advanced NET patients with low-to-intermediate grade. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.

Source

ANTI-CANCER DRUGS

Volume

28

Issue

2

URI

https://dx.doi.org/10.1097/CAD.0000000000000445
https://hdl.handle.net/20.500.12418/6867

Collections

  • Makale Koleksiyonu [5200]
  • Makale Koleksiyonu [5745]
  • Öksüz Yayınlar Koleksiyonu - WoS [6162]



DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 




Open Access Policy
About Open Access
User Guide
Contact

DSpace@Cumhuriyet

by OpenAIRE
Advanced Search

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypeDepartmentPublisherCategoryLanguageAccess TypeThis CollectionBy Issue DateAuthorsTitlesSubjectsTypeDepartmentPublisherCategoryLanguageAccess Type

My Account

LoginRegister

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 


|| Sivas Cumhuriyet University || Library || Open Access Policy || About Open Access || User Guide || OAI-PMH ||

Kütüphane ve Dokümantasyon Daire Başkanlığı, Sivas, Turkey
If you find any errors in content, please contact: acikerisim-yardim@cumhuriyet.edu.tr

Creative Commons License
DSpace@Cumhuriyet by Sivas Cumhuriyet University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

Sivas Cumhuriyet University is a member of the following institutions.


DSpace 6.3

tarafından İdeal DSpace hizmetleri çerçevesinde özelleştirilerek kurulmuştur.